Knapp, Peter https://orcid.org/0000-0001-5904-8699
Moe-Byrne, Thirimon https://orcid.org/0000-0002-2827-9715
Martin-Kerry, Jacqueline https://orcid.org/0000-0002-9299-1360
Sheridan, Rebecca https://orcid.org/0000-0002-7715-1224
Roche, Jenny https://orcid.org/0000-0003-1822-9519
Coleman, Elizabeth https://orcid.org/0000-0003-4210-1865
Bower, Peter https://orcid.org/0000-0001-9558-3349
Higgins, Steven https://orcid.org/0000-0003-0314-4846
Stones, Catherine https://orcid.org/0000-0002-9797-8587
Graffy, Jonathan
Preston, Jenny https://orcid.org/0000-0003-4800-234X
Gamble, Carrol https://orcid.org/0000-0002-3021-1955
Young, Bridget https://orcid.org/0000-0001-6041-9901
Perry, Daniel
Dahlmann-Noor, Annegret
Abbas, Mohamed
Khandelwal, Payal
Ludden, Siobhan
Azuara-Blanco, Augusto
McConnell, Emma
Mandall, Nicky
Lawson, Anna
Rogers, Chris A.
Smartt, Helena J. M.
Heys, Rachael
Stones, Simon R.
Taylor, Danielle Horton
Ainsworth, Sophie
Ainsworth, Jenny
Funding for this research was provided by:
Health Services and Delivery Research Programme (14/21/21)
Article History
Received: 15 March 2023
Accepted: 12 June 2023
First Online: 4 July 2023
Declarations
:
: The study protocol, protocol amendments, and informed assent/consent documents were reviewed and approved by the NHS Yorkshire and the Humber – Bradford Leeds Research Ethics Committee (17/YH/0082) and the Health Research Authority (IRAS ID 212761). The TRECA study was conducted in accordance with the principles of the Declaration of Helsinki, and all participants provided written informed consent to the host trial. No specific consent was required for the TRECA study, as approved by the Research Ethics Committee (17/YH/0082).
: All authors reviewed and approved the manuscript for publication.
: SRS is an employee of Envision Pharma Group, owns stock options in Envision Pharma Group, is a member of Savvy Cooperative, and is a trustee of RAiISE, a charitable incorporated organisation registered in England and Wales.No other authors have any competing interests to add.